Quicksilver Scientific

Free Shipping on Orders over $300 (Excludes , , )
Quicksilver Scientific Logo
Main Menu
Main Menu
0
0
Subtotal: 0.00

No products in the cart.

EDTA References

  1. Fabbrizzi L. Living in a cage is a restricted privilege. Top Curr Chem. 2012;323:127-66. View Abstract
  2. Suh JH. Dietary supplementation with (R)-alpha-lipoic acid reverses the age-related accumulation of iron and depletion of antioxidants in the rat cerebral cortex. Redox Rep. 2005;10(1):52-60. View Abstract
  3. Kartal SN. Removal of copper, chromium, and arsenic from CCA-C treated wood by EDTA extraction. Waste Management. 2003 Dec 31;23(6):537-46. View Abstract
  4. De Gregori I et al. Extractable copper, arsenic and antimony by EDTA solution from agricultural Chilean soils and its transfer to alfalfa plants (Medicago sativa L.). J Enviro Monitor 2004;6(1):38-47. View Full Paper
  5. Patrick L et al. Mercury toxicity and antioxidants: Part 1: role of glutathione and alpha-lipoic acid in the treatment of mercury toxicity.Altern Med Rev. 2002 Dec;7(6):456-71. View Full Paper
  6. Flora SJ et al. Heavy metal induced oxidative stress & its possible reversal by chelation therapy Indian J Med Res. 2008 Oct;128(4):501-23. View Abstract
  7. Ziegler EE et al. Absorption and retention of lead by infants. Pediatr Res. 1978 Jan; 12(1):29-34. View Article
  8. Jan AT et al. Heavy Metals and Human Health: Mechanistic Insight into Toxicity and Counter Defense System of Antioxidants. Int J Mol Sci. 2015;16(12):29592–29630 View Full Paper
  9. Flora S. Arsenic-induced oxidative stress and its reversibility. Free Radic. Biol. Med. 2011;51:257–281. View Abstract
  10. Ferrero ME. Rationale for the successful management of EDTA chelation therapy in human burden by toxic metals. Biomed Res Int. 2016;2016:8274504. View Full Paper
  11. Aheran GA et al. Mechanisms of heavy-metal sequestration and detoxification in crustaceans: a review.J Comp Physiol B. 2004 Aug;174(6):439-52. View Abstract
  12. Salehi B. Insights on the use of α-Lipoic acid for therapeutic purposes. Biomolecules. 2019 Aug 9;9(8). View Full Paper
  13. Seifar F. α-Lipoic acid, functional fatty acid, as a novel therapeutic alternative for central nervous system diseases: A review. Nutr Neurosci. 2019 May;22(5):306-316. View Abstract
  14. Flora SJ et al. Chelation in metal intoxication. Int J Environ Res Public Health. 2010;7(7):2745–2788 View Full Paper
  15. Foreman H et al. The metabolism of C14 labeled ethylene diamino tetraacetic acid in human beings. J Lab Clin Med. 1954;43:566–571. [View Abstract]
  16. Andersen O. Principles and recent developments in chelation treatment of metal intoxication. Chem Rev. 1999 Sep 8;99(9):2683-710. View Full Paper
  17. Jonah MM et al. Tissue of EDTA encapsulated within liposomes of varying surface Biochim Biophys Acta. 1975 Sep 2;401(3):336-48 View Abstract
  18. Jonah MM et al. Tissue distribution of EDTA encapsulated within liposomes containing glycolipids or brain phospholipids. Biochim Biophys Acta. 1978 Jul 3;541(3):321-33. View Abstract
  19. Patrick L. Mercury toxicity and antioxidants: Part 1: role of glutathione and alpha-lipoic acid in the treatment of mercury toxicity. Altern Med Rev. 2002 Dec;7(6):456-71. View Full Paper
  20. Breithaupt-Grogler K et al. Dose-proportionality of oral thioctic acid–coincidence of assessments via pooled plasma and individual data. Eur J Pharm Sci. 1999;8(1):57-65.View Abstract
  21. Schelkonogov VA et al. Liposomal form of lipoic acid: preparation and determination of antiplatelet and antioxidant activity Biomed Khim. 2016 Jul;62(5):577-583. View Abstract
  22. Külkamp IC. J Biomed Nanoencapsulation improves the in vitro antioxidant activity of lipoic acid.
  23. 2011 Aug;7(4):598-607. View Abstract
  24. Cranton EM et al. Free oxygen radical pathology and EDTA chelation therapy: mechanisms of action. Journal of Advancement in Medicine. 1998;11(4):277–310. View Full Paper
  25. Miller KL et al. Complementary and alternative medicine in cardiovascular disease: a review of biologically based approaches. Am Heart J. 2004 Mar; 147(3):401-11. View Abstract
  26. Roussel AM et al. EDTA chelation therapy, without added vitamin C, decreases oxidative DNA damage and lipid peroxidation.Altern Med Rev. 2009 Mar;14(1):56-61. View Abstract
  27. VE Kagan et al.Dihydrolipoic acid—a universal antioxidant both in the membrane and in the aqueous phase
  28. Biochem Pharmacol, 44 (1992), pp. 1637-1649 View Abstract
  29. Shay KP et al. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 2009;1790:1149–1160. View Full Paper
  30. Antioxidant and prooxidant activities of alpha-lipoic acid and dihydrolipoic acid. J Clin Biochem Nutr. 2015 Jul; 57(1): 21–26 View Abstract
  31. Goralska M et al. Alpha lipoic acid changes iron uptake and storage in lens epithelial cells. Exp. Eye Res. 2003, 76, 241–248. View Abstract
  32. Sun H et al. Alphalipoic Acid Prevents Oxidative Stress and Peripheral Neuropathy in Nab-Paclitaxel-Treated Rats through the Nrf2 Signalling Pathway. Oxid Med Cell Longev. 2019 Feb 10;2019:3142732. View Full Paper
  33. Rocamonde B et al. Neuroprotection of lipoic acid treatment promotes angiogenesis and reduces the glial scar formation after brain injury. Neuroscience. 2012;224:102–115. View Abstract
  34. Seifer F et al. α-Lipoic acid, functional fatty acid, as a novel therapeutic alternative for central nervous system diseases: A review. Nutr Neurosci. 2019 May;22(5):306-316 View Abstract
  35. Sloth-Nielsen J et al. Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis. Am J Surg. 1991 Aug;162(2):122-5. View Abstract
  36. Lamas GA et al. EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy.
  37. Am Heart J. 2014 Jul;168(1):37-44.e5. View Full Paper
  38. Chen KH et al. Effect of chelation therapy on progressive diabetic nephropathy in patients with type 2 diabetes and high-normal body lead burdens Am J Kidney Dis. 2012 Oct;60(4):530-8. View Abstract
  39. Zanella SG. Personalization of multiple sclerosis treatments: using the chelation therapy approach.Explore (NY). 2013 Jul-Aug;9(4):244-8. View Abstract
  40. Dinicola S et al. Alpha-Lipoic Acid downregulates IL-1 and IL-6 by DNA hypermethylation in SK-N-BE neuroblastoma cells. Antioxidant 2017, 6, 74. View Abstract
  41. Khalili M et al. Does lipoic acid consumption a_ect the cytokine profile in multiple sclerosis patients: A double-blind, placebo-controlled, randomized clinical trial. Neuroimmunomodulation 2014, 21, 291–296. View Abstract
  42. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995 Aug;19(2):227-50. View Abstract
  43. Bustamante J, Lodge JK, Marcocci L, et al. Alpha-lipoic acid in liver metabolism and disease. Free Radic Biol Med. 1998 Apr;24(6):1023-39. View Abstract
  44. Gurer H, et al. Antioxidant role of alpha-lipoic acid in lead toxicity. Free Radic Biol Med. 1999 Jul;27(1-2):75-81. View Abstract
  45. Spector AA et al. Membrane lipid composition and cellular function. J Lipid Res. 1985 Sep;26(9):1015-35 View Full Paper
  46. Porter CJ. Drug delivery to the lymphatic system. Crit Rev Ther Drug Carrier Syst. 1997;14(4):333-93 View Full Paper
  47. Ahn H, Park JH. Liposomal delivery systems for intestinal lymphatic drug transport. Biomater Res. 2016 Nov 23;20:36 View Full Paper
  48. Alyautdin R et al. Nanoscale drug delivery systems and the blood brain barrier. Int J Nanomedicine. 2014 Feb 7;9:795-811 View Full Paper
0
    0
    Your Cart
    You're 50.00 away from free shipping.
    Your cart is empty
    Continue Shopping
      Calculate Shipping
      Apply Coupon